ORPHELIA Pharma raises new money to accelerate its commercial and clinical operations
Paris, Lyon, December 14, 2021 – ORPHELIA Pharma, the French biopharmaceutical company dedicated to the development and commercialization of pediatric drugs in the fields of oncology and neurology, announces that it had made a capital increase to which all its shareholders subscribed : initiative OCTALFA and Gilles Alberici, Pierre Fabre Médicament/Pierre Fabre Invest, Ravenala holding (Alain Tornier), PAF Kapital (Jean-François Auffret) and Cemag (André Ulmann). The funds will be used to strengthen the company team and continue the clinical development of Kimozo®.
“I would like to thank all our shareholders for their renewed confidence”, said Mr. Hugues Bienaymé, CEO of ORPHELIA Pharma. “With their support, we will develop the company’s commercial infrastructure, set up new international partnerships and pursue our R&D efforts in the field of rare childhood diseases”.
Kimozo® is the first pediatric formulation of temozolomide developed with a patented formulation and adapted for the treatment of refractory or relapsed neuroblastoma in children. The product is the result of a partnership with Gustave-Roussy Hospital (Villejuif, France) and is currently in late clinical development.
About ORPHELIA Pharma
ORPHELIA Pharma is a biopharmaceutical company based in Paris and Lyon that develops and markets drugs for the treatment of paediatric and orphan diseases. ORPHELIA Pharma’s mission is to provide patients with essential hospital products in the fields of neurology and oncology, with formulations adapted to the paediatric population. With two products approved in the European Union and a project in an advanced phase of clinical development, ORPHELIA Pharma has recently set up regional agreements in the European Union, the USA and China and is carrying out research projects through academic and industrial partnerships.